胃と腸58巻6号

2023年06月発行

今月の主題 分類不能腸炎（IBDU）の現状と将来展望 序説

分類不能腸炎（IBDU）の現状と将来展望

著者： 平井郁仁¹ 芦塚伸也¹ 久能宣昭¹

所属機関： ¹福岡大学医学部消化器内科学講座

ページ範囲：P.709 - P.712

はじめに
　腸の炎症性疾患は原因や誘因が多岐にわたるため，しばしば確定診断が困難となる．しかし，最終的に診断できない症例に統一された呼称や定義は定まっていないのが現状である．本主題では“分類不能腸炎（IBDU）”として取り上げられているが，筆者は分類不能腸炎＝inflammatory bowel disease unclassified（以下，IBDU）とは考えていない．
　本稿では私見を含めて分類不能腸炎とIBDUの概念，定義，頻度や診断および経過観察中の留意点などについて述べたい．

参考文献

1）厚生労働科学研究費補助金 難治性疾患政策研究事業「難治性炎症性腸管障害に関する調査研究」（久松班）．令和4年度改訂版 潰瘍性大腸炎・クローン病診断基準・治療指針．令和4年度分担研究報告書，2023

2）Levine A, Koletzko S, Turner D, et al. ESPGHAN revised porto criteria for the diagnosis of inflammatory bowel disease in children and adolescents. J Pediatr Gastroenterol Nutr　58：795-806, 2014

3）Birimberg-Schwartz L, Zucker DM, Akriv A, et al. Development and validation of diagnostic criteria for IBD subtypes including IBD-unclassified in children：a multicentre study from the pediatric IBD Porto Group of ESPGHAN. J Crohns Colitis　11：1078-1084, 2017

4）Prenzel F, Uhlig HH. Frequency of indeterminate colitis in children and adults with IBD - a metaanalysis. J Crohns Colitis　3：277-281, 2009

5）平井郁仁，松井敏幸，宮岡正喜，他．indeterminate colitisの臨床的検討—その定義と頻度，臨床経過について．胃と腸　41：885-900, 2006

6）Ng SC, Leung WK, Shi HY, et al. Epidemiology of inflammatory bowel disease from 1981 to 2014：Results from a territory-wide population-based registry in Hong Kong. Inflamm Bowel Dis　22：1954-1960, 2016

7）Joossens S, Reinisch W, Vermeire S, et al. The value of serologic markers in indeterminate colitis：a prospective follow-up study. Gastroenterology　122：1242-1247, 2002

8）Carvalho RS, Abadom V, Dilworth HP, et al. Indeterminate colitis：a significant subgroup of pediatric IBD. Inflamm Bowel Dis　12：258-262, 2006

9）Henriksen M, Jahnsen J, Lygren I, et al. Change of diagnosis during the first five years after onset of inflammatory bowel disease：results of a prospective follow-up study（the IBSEN Study）. Scand J Gastroenterol　41：1037-1043, 2006

10）Everhov A°H, Sachs MC, Malmborg P, et al. Changes in inflammatory bowel disease subtype during follow-up and over time in 44,302 patients. Scand J Gastroenterol　54：55-63, 2019

11）Burisch J, Zammit SC, Ellul P, et al. Disease course of inflammatory bowel disease unclassified in a European population-based inception cohort：An Epi-IBD study. J Gastroenterol Hepatol　34：996-1003, 2019

12）Prideaux L, De Cruz P, Ng SC, et al. Serological antibodies in inflammatory bowel disease：a systematic review. Inflamm Bowel Dis　18：1340-1355, 2012

13）Hisabe T, Matsui T, Sakurai T, et al. Anti-Saccharomyces cerevisiae antibodies in Japanese patients with inflammatory bowel disease：diagnostic accuracy and clinical value. J Gastroenterol　38：121-126, 2003

14）Imakiire S, Takedatsu H, Mitsuyama K, et al. Role of serum proteinase 3 antineutrophil cytoplasmic antibodies in the diagnosis, evaluation of disease severity, and clinical course of ulcerative colitis. Gut Liver　16：92-100, 2022

15）Mitsuyama K, Niwa M, Masuda J, et al. Possible diagnostic role of antibodies to Crohn's disease peptide（ACP）：results of a multicenter study in a Japanese cohort. J Gastroenterol　49：683-691, 2014

16）Kuwada T, Shiokawa M, Kodama Y, et al. Identification of an anti-integrin αvβ6 autoantibody in patients with ulcerative colitis. Gastroenterology　160：2383-2394, 2021

17）Livanos AE, Dunn A, Fischer J, et al. Anti-integrin αvβ6 autoantibodies are a novel biomarker that antedate ulcerative colitis. Gastroenterology　164：619-629, 2023

18）Ouahed J, Spencer E, Kotlarz D, et al. Very early onset inflammatory bowel disease：A clinical approach with a focus on the role of genetics and underlying immune deficiencies. Inflamm Bowel Dis　26：820-842, 2020

19）Kammermeier J, Lamb CA, Jones KDJ, et al. Genomic diagnosis and care co-ordination for monogenic inflammatory bowel disease in children and adults：consensus guideline on behalf of the British Society of Gastroenterology and British Society of Paediatric Gastroenterology, Hepatology and Nutrition. Lancet Gastroenterol Hepatol　8：271-286, 2023

20）Umeno J, Hisamatsu T, Esaki M, et al. A hereditary enteropathy caused by mutations in the SLCO2A1 gene, encoding a prostaglandin transporter. PLoS Genet　11：e1005581, 2015

21）Arasawa S, Nakase H, Ozaki Y, et al. Mediterranean mimicker. Lancet　380：2052, 2012

22）Glocker EO, Kotlarz D, Boztug K, et al. Inflammatory bowel disease and mutations affecting the interleukin-10 receptor. N Engl J Med　361：2033-2045, 2009

23）Hamon A, Cazals-Hatem D, Stefanescu C, et al. Crohn-like disease affecting small bowel due to monogenic SLCO2A1 mutations：First cases of chronic enteropathy associated with SLCO2A1 gene（CEAS）in France. J Crohns Colitis　2022［Epub ahead of print］

24）Yanai S, Yamaguchi S, Nakamura S, et al. Distinction between chronic enteropathy associated with the SLCO2A1 gene and Crohn's disease. Gut Liver　13：62-66, 2019

25）Saito D, Hibi N, Ozaki R, et al. MEFV Gene-related enterocolitis account for some cases diagnosed as inflammatory bowel disease unclassified. Digestion　101：785-793, 2020

26）Egeberg A, Mallbris L, Warren RB, et al. Association between psoriasis and inflammatory bowel disease：a Danish nationwide cohort study. Br J Dermatol　175：487-492, 2016

27）?iburc? L, Bembea M, Zaha DC, et al. The treatment with interleukin 17 inhibitors and immune-mediated inflammatory diseases. Curr Issues Mol Biol　44：1851-1866, 2022

28）Shirwaikar Thomas A, Hanauer S, et al. Immune checkpoint inhibitor enterocolitis vs idiopathic inflammatory bowel disease. Clin Gastroenterol Hepatol　21：878-890, 2023